BMS Cancer Treatment Patent Survives Merck Attack, For Now
A Delaware federal judge on Tuesday refused to dismiss a suit by Bristol-Myers Squibb accusing Merck of infringing a patent for its immunotherapy cancer treatment, saying that although the patent is...To view the full article, register now.
Already a subscriber? Click here to view full article